![JCM | Free Full-Text | Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System JCM | Free Full-Text | Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System](https://www.mdpi.com/jcm/jcm-12-06089/article_deploy/html/images/jcm-12-06089-g001.png)
JCM | Free Full-Text | Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
![A drug that does exactly what it says on the tin — the story of allopurinol - The Pharmaceutical Journal A drug that does exactly what it says on the tin — the story of allopurinol - The Pharmaceutical Journal](https://pharmaceutical-journal.com/wp-content/uploads/2021/03/Screen-Shot-2021-03-18-at-16.52.54.png)
A drug that does exactly what it says on the tin — the story of allopurinol - The Pharmaceutical Journal
![PDF] Febuxostat compared with allopurinol in patients with hyperuricemia and gout. | Semantic Scholar PDF] Febuxostat compared with allopurinol in patients with hyperuricemia and gout. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/02f0afba074d21b85eaff785221e92f5949063ba/5-Table2-1.png)
PDF] Febuxostat compared with allopurinol in patients with hyperuricemia and gout. | Semantic Scholar
![Cost–effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore | Pharmacogenomics Cost–effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore | Pharmacogenomics](https://www.futuremedicine.com/cms/10.2217/pgs.15.125/asset/images/medium/figure2.gif)